HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $395
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio maintains a 'Buy' rating on Alnylam Pharmaceuticals (NASDAQ:ALNY), but has lowered the price target from $405 to $395.
October 11, 2023 | 10:28 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Alnylam Pharmaceuticals' price target has been lowered from $405 to $395 by HC Wainwright & Co., but the 'Buy' rating is maintained.
The news is directly about Alnylam Pharmaceuticals and is important for investors as it involves a change in price target by a prominent analyst. However, the impact on the stock price is neutral in the short term as the 'Buy' rating is maintained despite the lower price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100